Chemours misses by $0.10, beats on revs; guides FY23 EPS in-line (33.48 -1.45)
- Reports Q4 (Dec) net of breakeven, excluding non-recurring items, $0.10 worse than the S&P Capital IQ Consensus of $0.10; revenues fell 15.0% year/year to $1.34 bln vs the $1.27 bln S&P Capital IQ Consensus.
- Co issues in-line guidance for FY23, sees EPS of $3.80-4.29, excluding non-recurring items, vs. $4.06 S&P Capital IQ Consensus.
- "Our outlook contemplates a weaker start to 2023 with conditions improving in the second half of the year and continued secular growth in key parts of our TSS and APM businesses. Longer term, we continue to focus on improving the earnings profile of our TT business, while investing to capture growth from mega-trends underpinning TSS and APM."